NBIX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Neurocrine Biosciences Inc (NBIX) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has shown strong financial growth in the latest quarter and analysts maintain a generally positive outlook, the technical indicators are bearish, and options data suggests a negative sentiment. Additionally, there are no significant recent news or catalysts to drive immediate upside. Given the user's impatience and unwillingness to wait for optimal entry points, holding off on buying this stock for now is recommended.
The technical indicators are bearish. The MACD histogram is negative and contracting, RSI is neutral at 44.409, and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below the key pivot level of 132.56, with support at 124.66 and resistance at 140.461.
The company reported strong financial growth in Q4 2025, with revenue up 28.33% YoY, net income up 49.08% YoY, and EPS up 48.00% YoY. Analysts see long-term growth potential driven by Ingrezza and Crenessity.
Bearish technical indicators, weak short-term stock trend predictions (-2.29% in the next week, -9.85% in the next month), and no recent news or significant trading activity from hedge funds, insiders, or Congress.
In Q4 2025, revenue increased to $805.5M (+28.33% YoY), net income rose to $153.7M (+49.08% YoY), and EPS grew to 1.48 (+48.00% YoY). However, gross margin slightly declined to 97.82% (-0.71% YoY).
Analysts maintain a generally positive outlook, with several buy and outperform ratings. Price targets range from $140 to $204, with most analysts seeing the current price as undervalued. However, several firms have recently lowered price targets, reflecting cautious optimism.
